Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses ...
Jul 13, 2011
0
0
Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with ...
Dec 9, 2011
0
0
A Massachusetts General Hospital (MGH) research team, in collaboration with investigators at the Dana-Farber Cancer Institute, may have found a reason why the use of antiangiogenesis drugs - which has improved outcomes for ...
Nov 2, 2015
0
85
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain ...
Feb 14, 2013
0
0
Why are some bladder cancers resistant to a type of immunotherapy called immune checkpoint inhibitors? Penn State College of Medicine researchers have found that the genetic and pathologic diversity of cells within the tumor ...
Mar 31, 2023
0
37
Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Apr 19, 2021
0
137
An evolving understanding of cancer that incorporates the physical properties of tumors and their surrounding tissues into existing biologic and genetic models can direct cancer researchers down previously uncharted avenues, ...
Oct 30, 2020
0
38
Research led by Suresh Alahari, Ph.D., the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has found a new role for a protein discovered by his lab in preventing the ...
Jan 11, 2019
0
10
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in ...
Jun 21, 2022
0
285
Colorectal cancer is a common lethal disease, and treatment decisions are increasingly influenced by which genes are mutated within each patient. Some patients with a certain gene mutation benefit from a chemotherapy drug ...
Sep 24, 2019
0
113
